These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8798452)

  • 1. Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL.
    Simonian PL; Grillot DA; Merino R; Nuñez G
    J Biol Chem; 1996 Sep; 271(37):22764-72. PubMed ID: 8798452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death.
    Simonian PL; Grillot DA; Andrews DW; Leber B; Nuñez G
    J Biol Chem; 1996 Dec; 271(50):32073-7. PubMed ID: 8943258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2.
    Zha H; Aimé-Sempé C; Sato T; Reed JC
    J Biol Chem; 1996 Mar; 271(13):7440-4. PubMed ID: 8631771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL and Bcl-2.
    Simonian PL; Grillot DA; Nuñez G
    Oncogene; 1997 Oct; 15(15):1871-5. PubMed ID: 9362454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms.
    Minn AJ; Kettlun CS; Liang H; Kelekar A; Vander Heiden MG; Chang BS; Fesik SW; Fill M; Thompson CB
    EMBO J; 1999 Feb; 18(3):632-43. PubMed ID: 9927423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death.
    Reed JC; Zha H; Aime-Sempe C; Takayama S; Wang HG
    Adv Exp Med Biol; 1996; 406():99-112. PubMed ID: 8910675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bax-independent inhibition of apoptosis by Bcl-XL.
    Cheng EH; Levine B; Boise LH; Thompson CB; Hardwick JM
    Nature; 1996 Feb; 379(6565):554-6. PubMed ID: 8596636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL.
    Inohara N; Ekhterae D; Garcia I; Carrio R; Merino J; Merry A; Chen S; Núñez G
    J Biol Chem; 1998 Apr; 273(15):8705-10. PubMed ID: 9535847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax.
    Yin XM; Oltvai ZN; Korsmeyer SJ
    Nature; 1994 May; 369(6478):321-3. PubMed ID: 8183370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation.
    Ottilie S; Diaz JL; Chang J; Wilson G; Tuffo KM; Weeks S; McConnell M; Wang Y; Oltersdorf T; Fritz LC
    J Biol Chem; 1997 Jul; 272(27):16955-61. PubMed ID: 9202007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-XL protects BimEL-induced Bax conformational change and cytochrome C release independent of interacting with Bax or BimEL.
    Yamaguchi H; Wang HG
    J Biol Chem; 2002 Nov; 277(44):41604-12. PubMed ID: 12198137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BID: a novel BH3 domain-only death agonist.
    Wang K; Yin XM; Chao DT; Milliman CL; Korsmeyer SJ
    Genes Dev; 1996 Nov; 10(22):2859-69. PubMed ID: 8918887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death.
    Shangary S; Johnson DE
    Biochemistry; 2002 Jul; 41(30):9485-95. PubMed ID: 12135371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak.
    Cheng EH; Nicholas J; Bellows DS; Hayward GS; Guo HG; Reitz MS; Hardwick JM
    Proc Natl Acad Sci U S A; 1997 Jan; 94(2):690-4. PubMed ID: 9012846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BH3 domain of Bax is sufficient for interaction of Bax with itself and with other family members and it is required for induction of apoptosis.
    Simonen M; Keller H; Heim J
    Eur J Biochem; 1997 Oct; 249(1):85-91. PubMed ID: 9363757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides.
    Shangary S; Oliver CL; Tillman TS; Cascio M; Johnson DE
    Mol Cancer Ther; 2004 Nov; 3(11):1343-54. PubMed ID: 15542773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins.
    Moreau C; Cartron PF; Hunt A; Meflah K; Green DR; Evan G; Vallette FM; Juin P
    J Biol Chem; 2003 May; 278(21):19426-35. PubMed ID: 12642586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L).
    Chang BS; Kelekar A; Harris MH; Harlan JE; Fesik SW; Thompson CB
    Mol Cell Biol; 1999 Oct; 19(10):6673-81. PubMed ID: 10490606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing.
    Wang K; Gross A; Waksman G; Korsmeyer SJ
    Mol Cell Biol; 1998 Oct; 18(10):6083-9. PubMed ID: 9742125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins.
    Ottilie S; Diaz JL; Horne W; Chang J; Wang Y; Wilson G; Chang S; Weeks S; Fritz LC; Oltersdorf T
    J Biol Chem; 1997 Dec; 272(49):30866-72. PubMed ID: 9388232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.